Decui Pharmaceutical-B announced the interim performance for the six months ended June 30, 2024. During the period, the revenue decreased by 15.6% compared to the same period last year, from RMB 72.0 million to RMB 60.8 million. This decrease was mainly due to necessary price adjustments for Xevor® (Celecoxib) after its inclusion in the national medical insurance catalog, as well as a decrease in sales during the transition period of commercial cooperation with hansoh pharma. Research and development costs decreased from RMB 226.1 million to RMB 130.8 million due to improved research efficiency. Sales and distribution expenses also decreased to RMB 56.0 million due to reduced commercial milestone payments and cooperation in the Asia-Pacific region. The loss for the period decreased to RMB 167.0 million, an improvement from RMB 218.7 million in the same period last year. The company did not pay interim dividends and continues to focus on innovative research pipelines in oncology and immunology.

Decui Pharmaceutical-B announced the interim performance for the six months ended June 30, 2024. During the period, the revenue decreased by 15.6% compared to the same period last year, from RMB 72.0 million to RMB 60.8 million. This decrease was mainly due to necessary price adjustments for Xevor® (Celecoxib) after its inclusion in the national medical insurance catalog, as well as a decrease in sales during the transition period of commercial cooperation with hansoh pharma. Research and development costs decreased from RMB 226.1 million to RMB 130.8 million due to improved research efficiency. Sales and distribution expenses also decreased to RMB 56.0 million due to reduced commercial milestone payments and cooperation in the Asia-Pacific region. The loss for the period decreased to RMB 167.0 million, an improvement from RMB 218.7 million in the same period last year. The company did not pay interim dividends and continues to focus on innovative research pipelines in oncology and immunology.